Tempanor

Views & Analysis

A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.

News

Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.